Hattie Hayes

These findings could support gene therapies targeting CTG18.1 that are currently in development.

The ASTRA and accompanying POLARIS studies are actively enrolling patients.

According to Ocugen, the EMA has granted OCU410 and OCU410ST Advanced Therapy Medicinal Product classification.